TICKERNERD
Menu
MNOVMNOVHealthcare · Biotechnology

MNOV Stock Forecast: MediciNova, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$1.39
+1.46% on the day

The 3 Wall Street analysts covering MediciNova, Inc. hold a median 12-month price target of $10 — +619.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 94 of 100 as at 22 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$68.4M
Ticker Nerd rank
94 / 100
Median analyst target
$10
Analysts covering
3
Total return, dividends reinvested
1W
+6.1%
1M
+4.5%
YTD
+6.1%
1Y
+7.8%
From 52W high
−26.1%
From 52W low
+17.8%
$1.18
$1.88
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

MNOV stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores MediciNova, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
94 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
91
Growth
88
Size
80
Issuance
76
Revisions
70
Accruals
70
Quality
60
Momentum
58
Value
53

Volatility (91): The share price has been relatively steady.

Value (53): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

MNOV stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MNOV, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00$12.00Oct 25Jan 26Apr 26Jul 26MNOVHigh $11Median $10Low $6

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says3 analysts
3 Buy0 Hold0 Sell
Low $6Median $10High $11

The green dot is the last close — the median target sits +619.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
4 May 2026D. Boral CapitalMaintainsBuy$9.00
23 Mar 2026Maxim GroupReinstatesBuy$6.00
16 Mar 2026HC Wainwright & Co.InitiatesBuy—
30 Jan 2026D. Boral CapitalMaintainsBuy—
18 Dec 2025D. Boral CapitalMaintainsBuy—
8 Dec 2025D. Boral CapitalMaintainsBuy—
4 Nov 2025D. Boral CapitalMaintainsBuy—
31 Oct 2025D. Boral CapitalMaintainsBuy—
22 Sept 2025D. Boral CapitalMaintainsBuy—
27 Aug 2025D. Boral CapitalMaintainsBuy—
24 July 2025D. Boral CapitalMaintainsBuy—
16 June 2025B. Riley SecuritiesMaintainsBuy—
9 Apr 2025D. Boral CapitalMaintainsBuy—
14 Mar 2025D. Boral CapitalMaintainsBuy—
21 Feb 2025D. Boral CapitalMaintainsBuy—
6 Dec 2024D. Boral CapitalMaintainsBuy—
2 Dec 2024D. Boral CapitalInitiatesBuy—
10 Mar 2021Maxim GroupInitiatesBuy—
13 Mar 2020B. Riley FBRMaintainsBuy—
13 Mar 2020B. Riley SecuritiesMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MNOV appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

MNOV analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

MediciNova, Inc. (MNOV) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−5.8×

Cheaper than 90% of US stocks

Price / sales
74.3×

Cheaper than 5% of US stocks

Price / book
1.8×

Cheaper than 49% of US stocks

EV / EBITDA
−3.6×

Cheaper than 76% of US stocks

Growth & margins
Revenue growth (YoY)
240.6%

Higher than 96% of US stocks

Earnings growth (YoY)
—
Gross margin
9.0%

Higher than 9% of US stocks

Operating margin
−554.3%

Higher than 7% of US stocks

Net margin
7.6%

Higher than 65% of US stocks

Returns & dividend
Return on equity
−25.6%

Higher than 29% of US stocks

Return on assets
−16.4%

Higher than 22% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

MNOV vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
MNOVMediciNova, Inc.$68.4M
94
CSBRChampions Oncology, Inc.$68.4M
47
SPROSpero Therapeutics, Inc.$68.7M
83
CRDFCardiff Oncology, Inc.$67.8M
42
BOLDBoundless Bio, Inc.$67.2M
74
XBITXBiotech, Inc.$69.5M
32
RNTXRein Therapeutics, Inc.$70.0M
37

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own MediciNova, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MNOV news & analysis

MediciNova (MNOV) Reports Q2 Loss, Tops Revenue Estimates

Zacks Investment Research · 13 Aug 2026positive

MediciNova reported a Q2 loss of $0.05 per share, narrower than the Zacks Consensus Estimate of a $0.06 loss and improved from the $0.07 per-share loss a year earlier. The company also topped revenue estimates for the quarter.

Why it matters — The results reflect a better-than-expected quarter for MediciNova, with the loss narrowing from the prior-year period while revenue exceeded analyst forecasts.

FAQ

Frequently asked questions about MNOV stock

What is the MNOV stock price forecast for 2026-2027?

The 3 Wall Street analysts covering MediciNova, Inc. have a median 12-month price target of $10, with estimates ranging from $6 to $11. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MNOV stock a buy right now?

Of the 3 analysts covering MediciNova, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks MediciNova, Inc. 94 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MNOV?

As at 22 Aug 2026, MediciNova, Inc. ranks 94 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (91 of 100).

Will MNOV stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +619.4% from the last close, and Ticker Nerd's factor model ranks MediciNova, Inc. 94 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MNOV stock forecast for 2030?

No analyst covering MediciNova, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MNOV are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $11 over the next 12 months.

How has MNOV stock performed over the past year?

MediciNova, Inc. returned +7.8% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does MediciNova, Inc. do?

MediciNova Inc. is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for unmet medical needs.

What is the latest news on MNOV?

The most recent item we track (Zacks Investment Research, 13 Aug 2026): "MediciNova (MNOV) Reports Q2 Loss, Tops Revenue Estimates". MediciNova reported a Q2 loss of $0.05 per share, narrower than the Zacks Consensus Estimate of a $0.06 loss and improved from the $0.07 per-share loss a year earlier. The company also topped revenue estimates for the quarter.

Company

About MediciNova, Inc.

MediciNova Inc. is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for unmet medical needs. The company's primary mission is to improve patient outcomes through innovative treatments that address diverse and challenging conditions, particularly those in the fields of neurology, respiratory, and liver diseases. MediciNova's pipeline includes several investigational drugs targeting neurological disorders such as multiple sclerosis and amyotrophic lateral sclerosis (ALS), as well as potential treatments for respiratory ailments and non-alcoholic steatohepatitis (NASH). Headquartered in California, MediciNova plays a significant role in advancing medical research and development. Its work contributes to critical sectors of the healthcare industry by aiming to bring new solutions to the market that address areas with few existing treatment options. As a participant in the global biopharmaceutical landscape, MediciNova collaborates with research institutions and industry partners, enhancing its ability to innovate and fulfill its commitment to improving lives through science.

CEO Dr. Yuichi Iwaki M.D., Ph.D. · 6 employees · United States · https://medicinova.com